Received Apr 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | IM |
patient received Priorix intramuscularly instead of subcutaneously; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a 68-year-old female patient who received MMR (Priorix) for prophylaxis. On 08-APR-2025, the patient received Priorix (intramuscular). On 08-APR-2025, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: patient received Priorix intramuscularly instead of subcutaneously). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 16-APR-2025 The pharmacist called to report the following that the pharmacist had a question about the Priorix vaccine. The pharmacist had a patient that received it intramuscularly instead of subcutaneously which led to subcutaneous injection formulation administration by other route and the patient was wondering if he needed to be revaccinated.